Glaxo said on Wednesday the data, from an extended follow-up study, showed the longest duration of sustained neutralizing antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date. Experts believe that neutralizing antibodies — so-called because they have the ability to neutralize cancer-causing virus types and prevent them from infecting cells in the cervix — are essential for cervical cancer protection.
Glaxo says cervical cancer vaccine works for longer.